BI Asset Management Fondsmaeglerselskab A S Sells 22,086 Shares of Tenet Healthcare Corporation $THC

BI Asset Management Fondsmaeglerselskab A S lowered its position in Tenet Healthcare Corporation (NYSE:THC) by 17.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 103,906 shares of the company’s stock after selling 22,086 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Tenet Healthcare were worth $20,648,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in THC. Pinebridge Investments LLC purchased a new stake in Tenet Healthcare during the 4th quarter valued at $2,631,000. Prestige Wealth Management Group LLC boosted its stake in Tenet Healthcare by 9.2% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,972 shares of the company’s stock valued at $392,000 after purchasing an additional 166 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt boosted its stake in Tenet Healthcare by 107.8% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 38,650 shares of the company’s stock valued at $7,679,000 after purchasing an additional 20,050 shares during the last quarter. Vise Technologies Inc. boosted its stake in Tenet Healthcare by 42.3% during the 4th quarter. Vise Technologies Inc. now owns 3,038 shares of the company’s stock valued at $604,000 after purchasing an additional 903 shares during the last quarter. Finally, TD Asset Management Inc boosted its stake in Tenet Healthcare by 4.2% during the 4th quarter. TD Asset Management Inc now owns 126,882 shares of the company’s stock valued at $25,214,000 after purchasing an additional 5,130 shares during the last quarter. Hedge funds and other institutional investors own 95.44% of the company’s stock.

Tenet Healthcare Stock Up 0.5%

Shares of NYSE:THC opened at $162.20 on Friday. Tenet Healthcare Corporation has a 1 year low of $146.60 and a 1 year high of $247.21. The business has a 50 day simple moving average of $186.17 and a two-hundred day simple moving average of $200.75. The firm has a market capitalization of $13.97 billion, a PE ratio of 8.43, a price-to-earnings-growth ratio of 1.33 and a beta of 1.28. The company has a debt-to-equity ratio of 1.96, a current ratio of 1.36 and a quick ratio of 1.30.

Tenet Healthcare (NYSE:THC) last announced its earnings results on Thursday, April 30th. The company reported $4.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.21 by $0.61. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The business had revenue of $5.37 billion during the quarter, compared to analyst estimates of $5.39 billion. During the same quarter in the previous year, the business earned $4.36 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. On average, equities analysts predict that Tenet Healthcare Corporation will post 17.61 EPS for the current year.

Insider Activity at Tenet Healthcare

In other Tenet Healthcare news, Director Nadja West sold 3,000 shares of Tenet Healthcare stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $177.35, for a total value of $532,050.00. Following the transaction, the director directly owned 24,805 shares of the company’s stock, valued at approximately $4,399,166.75. The trade was a 10.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paola M. Arbour sold 6,500 shares of the business’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $238.43, for a total transaction of $1,549,795.00. Following the sale, the executive vice president directly owned 29,291 shares in the company, valued at $6,983,853.13. This trade represents a 18.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 23,138 shares of company stock worth $4,976,589. Insiders own 0.97% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. TD Cowen reissued a “buy” rating on shares of Tenet Healthcare in a report on Thursday, February 12th. UBS Group increased their price target on Tenet Healthcare from $260.00 to $288.00 and gave the company a “buy” rating in a report on Thursday, February 12th. KeyCorp decreased their target price on Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Mizuho raised their target price on Tenet Healthcare from $235.00 to $265.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. Finally, Guggenheim decreased their target price on Tenet Healthcare from $283.00 to $252.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Eighteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $244.16.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.